AZD5305 More Tolerable than Earlier PARP Agents.

Overview of attention for article published in Cancer Discovery, July 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Average Attention Score compared to outputs of the same age and source

So far, Altmetric has seen 7 X posts from 5 X users, with an upper bound of 22,240 followers.

RT @CD_AACR: #NewsInBrief: AZD5305 More Tolerable than 1st-Generation PARP Inhibitors. https://t.co/rsSAQUHdcn https://t.co/eBwMvXB7tk

RT @CD_AACR: #NewsInBrief: AZD5305 More Tolerable than 1st-Generation PARP Inhibitors. https://t.co/rsSAQUHdcn https://t.co/eBwMvXB7tk

New article: AZD5305 More Tolerable than 1st-Generation PARP Inhibitors https://t.co/R32LGghmmb #prostatecancer #oncology https://t.co/yHyCA3UHRa

New article: AZD5305 More Tolerable than 1st-Generation PARP Inhibitors https://t.co/9MoqurYBWc #breastcancer #oncology https://t.co/5exZzUZRPp

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.